We are on a journey to revolutionize neonatal intensive care
Every day, one in ten babies are born preterm, many of them with underdeveloped lungs that can advance to life-threatening conditions during their stay in the hospital and risk disabilities later on in life. They deserve a better start in life and health care professionals need support of modern technology to make life-changing decisions that can improve the health of these fragile patients.
Neola Medical’s groundbreaking innovation Neola® aims to upgrade today’s neonatal intensive care to include continuous lung monitoring and possibility of instant detection of life-threatening complications.
Learn more about investing in Neola Medical
Presentation of Neola
CEO of Neola Medical, Hanna Sjöström, presents Neola, a medical device for continuous monitoring of the lungs.
Lung monitoring with Neola
Neola Medicals’ proven technology uses laser spectroscopy to continuously measure lung volume changes and oxygen gas concentration in the lungs of preterm born infants. This is a safe and non-invasive method to monitor the lungs of these vulnerable patients in real time, providing the possibility of instant detection and treatment of complications and thus improving the care and decreasing the risk of disabilities later in life.
Certified according to ISO 13485
IECEE CB certificate by FORCE Technology
Selected as a Stanford Impact1 company
Latest News from Neola Medical
Neola Medical’s First American Board Member: A Key to Global Expansion
Neola Medical's expansion in the U.S. market is gaining momentum, with...
BioStock interview with new CFO at Neola Medical
Neola Medical has strengthened its management team, adding David Folkesson...
CEO Hanna Sjöström in an new interview with BioStock
"This is a step towards optimizing the conditions for a successful clinical...
For Investors
We are on a journey to revolutionize neonatal intensive care
Learn more about investing in Neola Medical